Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: AML

Interventions: Drug: Volasertib
Drug: Cytarabine
Drug: Idarubicin
Procedure: Bone Marrow Biopsy

First Posted Date: 2016-09-19

Last Posted Date: 2018-05-04

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT02905994

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)

Not Applicable

Completed

Conditions: ADHD
Tourette Syndrome

Interventions: Behavioral: Modified Comprehensive Behavioral Intervention for Tics
Behavioral: Comprehensive Behavioral Intervention for Tics

First Posted Date: 2016-09-14

Last Posted Date: 2021-09-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 17

Registration Number: NCT02900144

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

Not Applicable

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Ganaxolone

First Posted Date: 2016-09-14

Last Posted Date: 2019-02-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT02900092

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Phase 2

Recruiting

Conditions: Metastatic Malignant Neoplasm to Brain
Recurrent Brain Metastases
Progressive Brain Metastases

Interventions: Drug: Palbociclib
Drug: Pembrolizumab

First Posted Date: 2016-09-12

Last Posted Date: 2025-06-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 45

Registration Number: NCT02896335

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Collaborative Problem Solving vs. Positive Solutions for Families in Preschool Parent Groups

Not Applicable

Terminated

Conditions: Problem Behavior
Family Conflict
Child Behavior

Interventions: Behavioral: Collaborative Problem Solving
Behavioral: Positive Solutions For Families

First Posted Date: 2016-09-12

Last Posted Date: 2018-02-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 22

Registration Number: NCT02896426

Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: IMPROVED
Other: Usual Care

First Posted Date: 2016-09-08

Last Posted Date: 2021-11-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 150

Registration Number: NCT02891993

Locations: 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

Pembrolizumab In Central Nervous System Metastases

Phase 2

Active, not recruiting

Conditions: Brain Metastases

Interventions: Drug: Pembrolizumab
Radiation: MRI
Radiation: PET/CT
Procedure: Stereotactic Radiosurgery

First Posted Date: 2016-09-01

Last Posted Date: 2024-03-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 101

Registration Number: NCT02886585

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Priscilla Brastianos, Boston, Massachusetts, United States

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Phase 1

Active, not recruiting

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Hiltonol
Drug: Citarinostat
Biological: PVX-410
Drug: Lenalidomide

First Posted Date: 2016-09-01

Last Posted Date: 2024-04-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 19

Registration Number: NCT02886065

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Validation of Software-based Fusion of Ultrasound and MRI Images of the Prostate

Completed

Conditions: Prostate Cancer

First Posted Date: 2016-08-30

Last Posted Date: 2023-01-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT02882958

Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects

Completed

Conditions: HIV
Diastolic Dysfunction
Myocardial Fibrosis

Interventions: Other: Cardiac MRI/MRS

First Posted Date: 2016-08-22

Last Posted Date: 2019-10-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 48

Registration Number: NCT02874703

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy